Skip to content
// SEGAL HEALTH — THE BIOLOGICAL FRONTIER

We don't treat. We rebuild.

Segal Health applies the Segal engineering discipline to the hardest frontier of all — the human body. We print replacement organs, regrow tissue from a patient's own cells, and manufacture the molecules that sharpen the mind. Designed, fabricated, and delivered, under one roof.

Work with usExplore the divisions
Engineer the body. Extend the life.
3
Divisions, one biofabrication core
Cell → Cure
From a patient's own cells to therapy
2025
Founded
// 01 — THESIS

Aging and disease are engineering problems. We are building the machines that solve them.

Medicine still mostly manages decline — it slows what it cannot reverse and replaces what it cannot regrow. Segal Health rejects that ceiling. We treat the body as a system that can be re-fabricated: organs printed to spec, tissue regrown from a patient's own line, cognition tuned by molecules made to pharmaceutical tolerance.

The shared spine is biofabrication under control. The same discipline that prints a building and manufactures a satellite — survey, model, fabricate, deploy, operate — resolves a patient, compiles a therapy, and delivers it. Different feedstock. Same algorithm.

// HEADLINE METRIC

Time-to-therapy

The number that decides who lives. We compress it — donor waitlists to printed organs, decades of decline to cellular repair, lab discovery to GMP supply — and we are not optimizing the clinic. We are replacing its limits.

// 02 — DIVISIONS

Three divisions. One biofabrication core.

Each division is a full operator in its field — research through manufacture. Together they share the same biofabrication stack, the same regulatory discipline, and the same brand. Open any division for its technical brief.

Organs & Tissue

Segal Regenerative

Print the part. Replace the loss.

Autonomous 3D bioprinting of replacement organs and body parts. We image a patient, model the structure, and print living tissue from their own cells — ending the donor waitlist and the rejection that follows it.

  • Patient imaging → 3D tissue model → bioprint toolpath
  • Vascularized organ & cartilage scaffolds, printed to spec
  • Autologous cells — printed from the patient, no rejection
// THE HARD PROBLEM

Tissue thicker than the oxygen diffusion limit — about 200µm — dies at the center without a blood supply. That single constraint decides what can be printed today. Avascular cartilage needs no vasculature, so it is the honest place to start; solid organs wait on a printable blood supply.

0

Donors required — printed from the patient's own cells

Technical brief
  • RESEARCH

    The vascularization limit

    Oxygen and nutrients only diffuse ~200µm into tissue. Beyond that, cells at the core starve unless a vessel network feeds them. This is why cartilage is our first trial target and why solid organs remain research — not optimism, physics.

  • AVAILABLE

    Imaging-to-toolpath pipeline

    CT/MRI volumes are segmented into a patient-specific 3D geometry, then sliced to a layer-by-layer bioprint toolpath. The scan that resolves the anatomy produces the machine instructions that rebuild it.

  • TRIAL

    Autologous bioinks

    We print living cells encapsulated in hydrogel bioinks — GelMA, collagen, fibrin, alginate, and decellularized ECM — selected per tissue. Using the patient's own cells is what removes the immune rejection that follows donor tissue.

  • TRIAL

    FRESH / embedded printing

    Soft, low-viscosity tissues collapse under their own weight in air. We print them inside a support bath (FRESH / embedded printing) so delicate structures hold their shape until the matrix sets.

  • RESEARCH

    Sacrificial templating for vasculature

    To build a blood supply we print sacrificial channels into the construct, then dissolve them to leave a perfusable network that is lined with endothelial cells. It is the prerequisite for printing anything thicker than cartilage.

  • RESEARCH

    Maturation in perfusion bioreactors

    Printed constructs are matured in bioreactors that perfuse them while the tissue develops and remodels. A graft only advances when it meets sterility, viability, and mechanical release criteria.

  • RESEARCH

    The honest roadmap

    Cartilage graft (trial) → perfusable vascular lattice (research) → solid-organ constructs such as a renal unit (research). Each step is gated by the one before it. We do not skip the order.

Investigational. Trial- and research-stage programs are not available as treatments — for authorized clinical and research use only.

Stem Cells

Segal Longevity

Repair the cell. Extend the life.

Stem-cell research for human life extension. We reprogram and deploy a patient's own cells to repair tissue, reset biological age markers, and treat the diseases of aging at their cellular root rather than their symptoms.

  • Induced pluripotent stem-cell reprogramming
  • Partial cellular reprogramming for age reversal
  • Senescent-cell clearance & tissue regeneration
// THE HARD PROBLEM

Resetting a cell's age without erasing what the cell is. Full reprogramming rolls cells all the way back to a stem state — which restores youth but destroys function and risks teratoma. The entire program is built around resetting age markers while holding cell identity fixed. Every claim here is pre-clinical.

iPSC

Patient-derived lines — the engine of repair

Technical brief
  • RESEARCH

    iPSC reprogramming (Yamanaka / OSKM)

    We derive patient-matched cell lines by inducing pluripotency with the Yamanaka factors (OSKM). These autologous lines are the feedstock for repair — the patient's own cells, not a donor's.

  • RESEARCH

    Partial / transient reprogramming

    Factors are applied cyclically and briefly — never to completion — to roll back epigenetic age while the cell keeps its identity. This restraint is the central safety constraint: full reprogramming risks loss of function and teratoma, so we deliberately stop short.

  • RESEARCH

    Epigenetic clocks as the readout

    Success is defined by DNA-methylation age — an epigenetic clock — not by hope. If a therapy does not move the clock without changing the cell, it has not worked. The biomarker is the goalpost.

  • RESEARCH

    Senescence, SASP & senolytic clearance

    Worn-out senescent cells secrete an inflammatory program (SASP) that drives age-related disease in neighboring tissue. We clear them with senolytics, then reseed repair with fresh autologous stem cells.

  • RESEARCH

    Honest first targets

    We begin with immune-privileged and accessible tissue — the eye and the immune system — before any systemic application. Starting where delivery and safety are most tractable is the defensible order. Pre-clinical.

Investigational. Trial- and research-stage programs are not available as treatments — for authorized clinical and research use only.

Mind & Cognition

Segal Neuropharm

Manufacture the molecule. Sharpen the mind.

Precision pharmaceutical manufacturing for the mind. We produce GMP-grade stimulants and psychedelic compounds — for focus, imagination, and the treatment of depression, PTSD, and addiction — to a purity and consistency the clinic can trust.

  • GMP stimulant manufacturing for focus & ADHD
  • Psychedelic therapeutics for depression, PTSD & addiction
  • Analytically-pure synthesis with full chain-of-custody
// THE HARD PROBLEM

In neuropharmaceuticals, consistency and analytical purity are the therapeutic — and variability is the failure mode. A dose that differs batch to batch is a different experiment every time. Our product is not a molecule in the abstract; it is the same molecule, to the same purity, every time.

GMP

Pharmaceutical-grade, every batch, fully assayed

Technical brief
  • AVAILABLE

    Purity is the product

    For CNS-active compounds the margin between effect and harm is narrow, so reproducibility is the whole game. We treat identity, potency, and purity as the deliverable, not a checkbox after it.

  • AVAILABLE

    GMP under ICH-aligned quality systems

    Manufacturing runs under ICH-aligned GMP with documented in-process controls and full release testing on every batch. The process is designed alongside the analytical method that will later prove it.

  • AVAILABLE

    Chiral / enantiomeric purity

    Many CNS molecules are chiral — and the wrong isomer is often inert or harmful. Single-enantiomer control is therefore a core capability and a release criterion, not an afterthought.

  • AVAILABLE

    Analytical stack & chain-of-custody

    Identity and purity are confirmed by HPLC, LC-MS, and NMR against reference standards. Controlled substances move under full chain-of-custody with DEA-schedule handling, released only to licensed partners.

  • TRIAL

    Portfolio, framed by stage

    GMP stimulants for ADHD and focus are available to licensed partners today. Standardized psilocybin and MDMA for treatment-resistant depression, PTSD, and addiction are trial-stage, supplied only to authorized clinical sites.

Controlled substance. Manufactured under applicable regulation for authorized clinical and research use, and supplied only to licensed partners and authorized sites.

// 03 — PLATFORM

One algorithm. Different biology.

Our core competency is biofabrication from design to delivery, re-skinned per division. An organ, a cell line, and a molecule are the same problem with different feedstock. We solve it once, then specialize.

01RESOLVE
02DESIGN
03FABRICATE
04VALIDATE
05DELIVER
01In use today

Resolve the patient & target

Imaging, sequencing, and assays resolve a body or a molecule to tolerance, then compile the result straight into a fabrication plan — tissue model, cell protocol, or synthesis route.

02In use today

Fabricate from living & molecular feedstock

Bioprinters lay down vascularized tissue; reactors reprogram cells; GMP lines synthesize pharmaceuticals. Vertically integrated, so nothing critical waits on an outside supplier.

03In use today

Validate to clinical & regulatory standard

Every output is assayed, characterized, and documented — sterility, potency, purity, identity — against the standard its pathway demands. We mark trial-stage work as trial-stage.

04Roadmap

Deliver and follow the outcome

Printed grafts to the surgical suite, cell therapies to the clinic, pharmaceuticals to licensed partners — tracked through administration and beyond. We own the outcome, not just the handoff.

// 04 — THE BIOFABRICATION CORE

The same five steps, three feedstocks.

The same five steps run in every division — an organ, a cell line, and a molecule are the same problem with different inputs. Each step below shows the concrete method per division. Badges mark how operational the method is, not whether a product is available; program stage is tracked in Pipeline and Programs.

// METHOD MATURITY — not product readiness. Trial- and research-stage programs remain staged in Pipeline and Programs.

01

Resolve

In use today
Organs & Tissue

CT/MRI volumetric imaging → segmentation → patient-specific geometry; cell biopsy.

How it works

We reconstruct the target structure from a patient's own scans, segment the anatomy, and derive an exact 3D geometry. A matched biopsy supplies the autologous cells the graft will be built from.

Stem Cells

Whole-genome & epigenetic profiling; methylation-age readout; cell-line derivation.

How it works

We profile a patient-derived cell line and read its biological age from DNA-methylation patterns — an epigenetic clock. That age signal becomes the target the therapy is designed to move. Pre-clinical.

Mind & Cognition

Target compound spec; reference-standard characterization; synthesis-route selection.

How it works

We fix the exact molecule — including the intended single enantiomer — against a characterized reference standard, then select a route to reach it. Identity is defined before anything is made.

02

Design

In use today
Organs & Tissue

Geometry → voxel/STL model → slicer → toolpath; bioink + sacrificial-channel planning.

How it works

The geometry is sliced into a layer-by-layer toolpath with a bioink chosen per tissue. Where tissue must be perfused, sacrificial channels are planned into the model — the negative space that later becomes vasculature.

Stem Cells

Reprogramming-factor protocol design; senescence-targeting strategy.

How it works

We design which reprogramming factors to apply, at what dose and for how long, to reset age markers without changing what the cell is. In parallel we plan which senescent cells to clear. Pre-clinical.

Mind & Cognition

Route design, reaction sequence, in-process control points, analytical-method development.

How it works

We lay out the reaction sequence with defined in-process control points and develop the analytical methods that will later prove identity, potency, and purity. The test is designed alongside the process.

03

Fabricate

In use today
Organs & Tissue

Extrusion / FRESH embedded printing of hydrogel bioinks with encapsulated autologous cells.

How it works

Soft bioinks — GelMA, collagen, fibrin, decellularized ECM — are extruded, often into a support bath so delicate structures hold their shape. The patient's own cells are encapsulated in the matrix as it prints.

Stem Cells

Ex-vivo expansion; partial/transient reprogramming; senolytic clearance; construct seeding.

How it works

Patient cells are expanded ex vivo, then cyclically and transiently exposed to reprogramming factors to roll back age markers. Senescent cells are cleared and the repaired population is reseeded. Pre-clinical.

Mind & Cognition

GMP synthesis lines: reaction, purification, isolation.

How it works

The compound is synthesized on vertically integrated GMP lines, then purified and isolated to the defined specification. Every step runs under documented quality control.

04

Validate

In use today
Organs & Tissue

Sterility, viability, mechanical & perfusion testing; maturation in perfusion bioreactors.

How it works

Constructs are tested for sterility, cell viability, and mechanical properties, then matured in perfusion bioreactors that feed the tissue as it develops. A graft only advances if it meets release criteria.

Stem Cells

Identity & karyotype stability, age-marker reversal assays, off-target / safety screening.

How it works

We confirm the cells kept their identity and a stable karyotype, measure the age-marker reversal we set out to achieve, and screen for off-target effects — no loss of identity, no teratoma. Pre-clinical.

Mind & Cognition

Identity, potency, purity & chiral purity via HPLC / LC-MS / NMR; ICH-aligned release.

How it works

Every batch is released against identity, potency, and purity — including enantiomeric purity — using HPLC, LC-MS, and NMR against reference standards. Controlled substances move under full chain-of-custody.

05

Deliver

Roadmap
Organs & Tissue

Implant-ready graft to the surgical suite.

How it works

Released grafts are delivered sterile and implant-ready to the operating surgeon. Closed-loop follow-up of long-term graft outcome is roadmap.

Stem Cells

Autologous therapy to the clinic.

How it works

Matched autologous therapy returns to the treating clinic for the specific patient it was built from. Delivery at clinical scale is roadmap; current work is pre-clinical.

Mind & Cognition

Assayed batches to licensed partners under chain-of-custody.

How it works

Fully assayed batches ship to licensed clinical and research partners under chain-of-custody. Outcome data flows back from authorized sites; closed-loop integration is roadmap.

// 05 — RESEARCH

The primitives under the platform.

Each division is assembled from shared capabilities — the machines and methods we built to make the algorithm run. Staged honestly: the research primitives are the science still being proven; the manufacturing primitives ship today to licensed partners.

AVAILABLERegenerative

Imaging-to-toolpath compiler

Patient scan to printable geometry.

Converts CT/MRI volumes into segmented, patient-specific 3D models and slices them to a bioprint toolpath. The same compiler that resolves anatomy produces the machine instructions that rebuild it.

TRIALRegenerative

Autologous bioink system

The patient's own cells in a printable matrix.

Encapsulates autologous cells in hydrogel bioinks — GelMA, collagen, fibrin, dECM — tuned per tissue. Using the patient's own cells removes the rejection that follows donor tissue.

RESEARCHRegenerative

Perfusable vascular lattice

Sacrificial-channel microvasculature.

Prints sacrificial channels that are later dissolved and endothelialized into a perfusable network. It is the prerequisite for keeping solid organs alive beyond the ~200µm oxygen diffusion limit.

RESEARCHLongevity

Partial-reprogramming protocol

Age-marker reset without identity loss.

Applies reprogramming factors transiently and cyclically to roll back epigenetic age while preserving cell identity. Full reprogramming is deliberately avoided — it risks loss of function and teratoma.

RESEARCHLongevity

Senolytic clearance

Targeted removal of senescent cells.

Selectively clears senescent cells and their inflammatory SASP signaling, then reseeds repair with fresh autologous stem cells. Targets the cellular drivers of age-related decline rather than the symptoms.

RESEARCHLongevity

Epigenetic-age assay

The longevity readout.

Reads biological age from DNA-methylation patterns to define whether a therapy actually moved the target. It is the biomarker that turns 'younger' into something measurable.

AVAILABLENeuropharm

GMP synthesis line

Vertically integrated, fully assayed manufacturing.

Produces CNS-active compounds under ICH-aligned GMP with documented in-process controls and batch release. Vertical integration keeps identity, potency, and purity under one roof.

AVAILABLENeuropharm

Chiral-purity analytics

Single-enantiomer control.

Resolves and quantifies enantiomers by HPLC, LC-MS, and NMR against reference standards. For many CNS molecules the wrong isomer is inert or harmful, so single-enantiomer control is a release criterion.

AVAILABLENeuropharm

Chain-of-custody system

Controlled-substance tracking.

Tracks scheduled materials end to end and enforces DEA-schedule handling, releasing only to licensed partners and authorized sites. The audit trail is part of the product.

// 06 — PIPELINE

What we are bringing to the clinic.

The divisions ship through a shared development pipeline. Stage is marked honestly — clinically available, in trial, or in research — because in medicine, overstatement costs lives. Each program lists how it works and what has to be true next.

TRIALRegenerative

Bioprinted Cartilage Graft

Patient-matched cartilage for joint and airway repair, printed from autologous chondrocytes. First-in-human trials underway with a partnered surgical network.

// HOW IT WORKS
Chondrocytes from the patient are printed into a patient-matched scaffold. Cartilage is avascular, so the graft needs no built-in blood supply to survive — which is why it is the first tissue we take to trial.
// WHAT HAS TO BE TRUE NEXT
Read out first-in-human graft integration and durability before widening indications.
Trial enrollment
RESEARCHRegenerative

Printed Renal Construct

A vascularized kidney construct printed from a patient's own cells — the path off the dialysis machine and the transplant list. Pre-clinical.

// HOW IT WORKS
The construct is printed around a sacrificial channel network that is dissolved to leave perfusable vasculature, feeding the tissue past the ~200µm diffusion limit that kills thick constructs.
// WHAT HAS TO BE TRUE NEXT
Demonstrate a stably perfused, filtering construct in pre-clinical models.
Research brief
RESEARCHLongevity

Age-Reversal Cell Therapy

Partial reprogramming of patient-derived cells to reset age markers and regenerate tissue, beginning with the eye and immune system. Pre-clinical.

// HOW IT WORKS
Patient-derived cells are partially reprogrammed — factors applied transiently — to reset epigenetic age markers without erasing cell identity, then returned to repair tissue.
// WHAT HAS TO BE TRUE NEXT
Show durable age-marker reversal with no loss of identity and no teratoma in pre-clinical models.
Research brief
CLINICALNeuropharm

Cognition Stimulant — GMP

Pharmaceutical-grade stimulant therapeutics for ADHD and focus disorders, manufactured to full GMP and supplied to licensed clinical partners.

// HOW IT WORKS
A single-enantiomer stimulant is synthesized on GMP lines and released only after identity, potency, and chiral-purity testing — every batch held to the same specification.
// WHAT HAS TO BE TRUE NEXT
Maintain batch-to-batch consistency across scaled supply to licensed partners.

Controlled substance. Manufactured under applicable regulation for authorized clinical and research use, and supplied only to licensed partners and authorized sites.

Partner supply
TRIALNeuropharm

Psilocybin Therapeutic

Standardized, analytically-pure psilocybin for treatment-resistant depression and PTSD, supplied to authorized clinical-trial sites under chain-of-custody.

// HOW IT WORKS
Psilocybin is produced to a fixed analytical standard so every dose at an authorized trial site is identical. Consistency is the therapeutic variable, so purity is the deliverable.
// WHAT HAS TO BE TRUE NEXT
Supply standardized material to authorized treatment-resistant-depression and PTSD trials.

Controlled substance. Manufactured under applicable regulation for authorized clinical and research use, and supplied only to licensed partners and authorized sites.

Trial supply
TRIALNeuropharm

MDMA-Assisted Therapy Supply

GMP MDMA for assisted psychotherapy in PTSD, produced to pharmaceutical purity for authorized clinical programs and their regulated administration.

// HOW IT WORKS
GMP MDMA is manufactured to pharmaceutical purity and moved under chain-of-custody for assisted-psychotherapy protocols, where the dose must be identical and accountable at every step.
// WHAT HAS TO BE TRUE NEXT
Sustain release-grade purity for authorized assisted-therapy programs.

Controlled substance. Manufactured under applicable regulation for authorized clinical and research use, and supplied only to licensed partners and authorized sites.

Trial supply
// 07 — PROGRAMS

Selected programs.

Across the three divisions, marked honestly by stage. Every claim is one we can defend to a regulator and a patient alike.

IN TRIALRegenerative

Autograft One

Bioprint Suite — Cambridge, MA

Patient-matched cartilage graft, printed in 9 hours from autologous cells.

First production deployment of the Segal bioprinter. Imaging to sterile, implant-ready graft with no donor and no immunosuppression — currently in first-in-human surgical trials.

RESEARCHRegenerative

Vascular Lattice

Bioprint Suite — Cambridge, MA

Perfusable microvascular network — the prerequisite for printing solid organs.

The hard problem under every printed organ: getting blood to the center of the tissue before it dies. Our perfusable lattice keeps thick constructs alive long enough to mature.

RESEARCHLongevity

Reset

Longevity Lab — South San Francisco, CA

Partial reprogramming protocol; biological-age reversal in patient-derived lines.

Pre-clinical program resetting epigenetic age markers in a patient's own cells without erasing cell identity — restoring youthful function to aged tissue, starting with the eye.

RESEARCHLongevity

Clearance

Longevity Lab — South San Francisco, CA

Targeted senescent-cell removal to regenerate aged tissue.

Selectively clearing the worn-out cells that drive age-related disease, then seeding repair with fresh patient-derived stem cells. Pre-clinical, with biomarkers tracked end to end.

AVAILABLENeuropharm

Clarity

GMP Plant — Basel, CH

GMP stimulant therapeutics for ADHD and focus, supplied to licensed partners.

Vertically integrated, fully-assayed manufacturing of cognition-supporting stimulants for clinical use — every batch characterized for identity, potency, and purity under full chain-of-custody.

IN TRIALNeuropharm

Aperture

GMP Plant — Basel, CH

Pharmaceutical-grade psychedelics for depression, PTSD & addiction trials.

Standardized psilocybin and MDMA produced to analytical purity for authorized clinical-trial sites — expanding access to assisted therapy for conditions conventional drugs fail to reach.

// 08 — PRINCIPLES

The staging ethic, stated out loud.

Credibility in medicine is a discipline, not a slogan. These are the rules we hold ourselves to — and the reason every claim on this page carries a stage.

01

We label trial-stage work as trial-stage.

Every program carries one of AVAILABLE, CLINICAL, TRIAL, or RESEARCH. When a stage is uncertain, we label down, not up.

02

We compress time-to-therapy, not the truth about it.

Speed is the point of the platform. It is never a reason to imply a capability is more mature than it is.

03

Every claim is one we can defend to a regulator and a patient.

If a statement would not survive both audiences, it does not ship. Qualitative honesty beats quantitative theater.

04

We start where the biology is honest.

Avascular cartilage before solid organs; the eye before the whole body; licensed partners before open supply. The first target is the defensible one.

// 09 — ENGAGE

Rebuild the body with us.

We work with clinicians, research institutions, regulators, and investors who measure outcomes in lives restored and years returned. If that's you — whether you bring a surgical network, a trial site, or capital — the conversation is short.

Direct to the founding team. No newsletter, no funnel.

Email the founding team →